Results 211 to 220 of about 81,076 (308)

Signal Transducer and Activator of Transcription (STAT) Proteins Regulate Mucosal‐Associated Invariant T (MAIT) Cell Function

Immunology, EarlyView.
Integrated transcriptomic, proteomic and flow cytometry analyses reveal that STAT1 negatively regulates MAIT cell effector and glycolytic functions, while STAT3, STAT5 and HIF1α act as positive modulators. Targeting these pathways may offer new strategies to restore MAIT cell function in immune dysregulation and cancer.
Olivia J. Cheng, Eimear K. Ryan, Michael Bennett, Christy Clutter, Jackson G. Cacioppo, Jeffrey Aubé, Andy E. Hogan, Daniel T. Leung   +7 more
wiley   +1 more source

[Renewed increase in new Janus kinase inhibitor prescriptions : Analysis of the German RHADAR registry]. [PDF]

Z Rheumatol
Strunz PP, Risser LM, Englbrecht M, Witte T, Fröhlich M, Schmalzing M, Gernert M, Heck J, Bartz-Bazzanella P, von der Decken C, Karberg K, Gauler G, Späthling-Mestekemper S, Kuhn C, Vorbrüggen W, Welcker M, Kleinert S.   +16 more
europepmc   +1 more source

USP18 mediates high glucose‐induced cardiomyocyte injury by regulating the JAK/STAT signaling pathway through stabilizing FOXC2 expression

Journal of Diabetes Investigation, EarlyView.
USP18 upregulation stabilizes FOXC2 expression by deubiquitination to inactivate the JAK2/STAT3 pathway, thereby inhibiting HG‐induced NMVM apoptosis, inflammation, oxidative stress, and fibrosis. ABSTRACT Background Cardiomyopathy is one of the complications of diabetes, among which myocardial fibrosis is the most typical feature.
Zhengrong Xu, Weidong Ren, Jun Gu, Wenjuan Deng, Lijuan Zuo   +4 more
wiley   +1 more source

Aggressive cutaneous squamous cell carcinoma in a patient on Janus-kinase inhibitor therapy. [PDF]

JAAD Case Rep
Aragon Sierra AM, Donohoe KJ, Canaday DJ, Gomez ED, Jalisi SM, Koomey MM, Aviles VM, Yu KK.   +7 more
europepmc   +1 more source

Association of glucagon‐like peptide‐1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
This TriNetX (US, 2016–2023) study compared clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes treated with GLP‐1 receptor agonists vs DPP4 inhibitors. ABSTRACT Objectives To evaluate whether glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are associated with improved survival and renal outcomes in patients with ...
Yu‐Ting Yu, Ying Chun Lee, Yu‐Wei Fang, Wen‐Hui Hsieh, Ming‐Hsien Tsai   +4 more
wiley   +1 more source

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin, Marie Tauber, Robert Sidbury, Jonathan I. Silverberg, Kim A. Papp, Diamant Thaçi, Marjolein S. De Bruin‐Weller, Adam Reich, Ketty Peris, Kirk Barber, Ryszard Galus, Andrzej Kaszuba, Matthew Zirwas, Walter K. Nahm, Gretel Trullenque, Laura Maintz, Sady Alpizar, Sang Wook Son, Vivian Laquer, Linda Stein Gold, Soo Yeon Cheong, Anna Ryzhkova, Agnes Drahos, Liliana Ulianov, Christophe Piketty   +24 more
wiley   +1 more source

Direct Effects of the Janus Kinase Inhibitor Baricitinib on Sensory Neurons. [PDF]

Int J Mol Sci
Vazquez E, Richter F, Natura G, König C, Eitner A, Schaible HG.   +5 more
europepmc   +1 more source

Predictive Factors of Response and Real‐World Experience of Baricitinib on Alopecia Areata: A Single Tertiary Center Study on a 72 Patients' Cohort

International Journal of Dermatology, EarlyView.
Alonso García‐Núñez, Antonio Alcalá Ramírez Del Puerto, Roberto Daza‐García, María Teresa Monserrat‐García, Mercedes Morillo‐Andújar, Javier Jesús Domínguez‐Cruz, Román Barabash‐Neila   +6 more
wiley   +1 more source

Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The current study found no evidence of cumulative increased safety risks with upadacitinib 15 or 30 mg for up to 6 years and over 9000 patient‐years of safety data in adults and adolescents. There were low rates of adjudicated major adverse cardiovascular events, adjudicated thromboembolic events and malignancies. Abstract Background Atopic dermatitis (
Christopher G. Bunick, Alan D. Irvine, Jonathan I. Silverberg, Emma Guttman‐Yassky, Mona Shahriari, Xinghua Gao, Stephan Weidinger, Norito Katoh, Namita Vigna, Deanne M. Dilley, Elvira D'Andrea, Henrique D. Teixeira, Andrew M. Platt, Gweneth F. Levy   +13 more
wiley   +1 more source

Corrigendum to 'Combination of Janus kinase inhibitor and biologic for recalcitrant severe atopic dermatitis'. [PDF]

J Eur Acad Dermatol Venereol
europepmc   +1 more source